Vadastuximab talirine
Vadastuximab talirine is an antibody-drug conjugate (ADC) designed for the treatment of acute myeloid leukemia (AML). It is composed of a monoclonal antibody targeting the CD33 antigen, which is commonly expressed on the surface of AML cells, linked to a cytotoxic agent.
Mechanism of Action
Vadastuximab talirine works by specifically binding to the CD33 antigen on the surface of AML cells. Upon binding, the ADC is internalized into the cell, where the cytotoxic agent is released. This agent then induces DNA damage, leading to cell death. The targeted approach aims to minimize damage to normal, healthy cells, thereby reducing the side effects typically associated with conventional chemotherapy.
Development and Clinical Trials
Vadastuximab talirine was developed by Seattle Genetics. It has undergone various phases of clinical trials to evaluate its safety and efficacy in patients with AML. The results from these trials have been mixed, with some showing promising outcomes in terms of remission rates and overall survival, while others have raised concerns about potential side effects and toxicity.
Side Effects
Common side effects of vadastuximab talirine include neutropenia, thrombocytopenia, and anemia. More severe side effects can include hepatotoxicity and veno-occlusive disease (VOD). Due to these potential risks, the use of vadastuximab talirine is typically reserved for patients who have not responded to other treatments or who are ineligible for other forms of therapy.
Current Status
As of the latest updates, vadastuximab talirine is not yet approved by the Food and Drug Administration (FDA) for general use. Ongoing research and additional clinical trials are being conducted to further assess its safety and efficacy.
Related Pages
- Acute myeloid leukemia
- Antibody-drug conjugate
- CD33
- Seattle Genetics
- Chemotherapy
- Neutropenia
- Thrombocytopenia
- Anemia
- Hepatotoxicity
- Veno-occlusive disease
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
